CytoDyn Inc.

CytoDyn Inc. is a biotechnology company focused on developing innovative treatments for various therapeutic indications, including HIV, oncology, and inflammation. The company's lead candidate, Leronlimab (PRO 140), is a novel humanized monoclonal antibody targeting the CCR5 receptor. CytoDyn is committed to improving patients' quality of life through collaboration and a unified vision of serving humanity.